EGFR and head and neck cancer: A phase III clinical trial of NIR-PIT using the epidermal growth factor receptor (EGFR) -targeted antibody-IR700 conjugate, cetuximab-IR700, in patients with inoperable head and neck cancer is underway (https://clinicaltrials.gov/ct2/show/NCT03769506).